西測測試(301306.SZ)2022年度扣非淨利潤預降26.14%-37.63%
格隆匯1月31日丨西測測試(301306.SZ)公佈,預計2022年度歸屬於上市公司股東的淨利潤6200萬元–6700萬元,同比下降0.02%-7.48%;扣除非經常性損益後的淨利潤3800萬元–4500萬元,同比下降26.14%-37.63%。
報吿期內,公司淨利潤下降的主要原因系2022年公司首次承接zzkk項目前期研發費用及材料成本投入較大,毛利較低,以及子公司新能力建設、電子裝聯業務尚未形成規模收入虧損所致。
報吿期內,預計非經常性損益對公司淨利潤的影響金額約2300萬元,主要系收到政府補助所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.